Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best small cap stocks with biggest upside potential. On August 4, Dyne Therapeutics announced that its investigational therapy, called DYNE-251, received Breakthrough Therapy Designation from the US FDA. This designation is for treating Duchenne muscular dystrophy/DMD patients whose condition is amenable to exon 51 skipping.

This marked the second such designation for the company, as its other lead program, called DYNE-101, also received the designation earlier in 2025 for myotonic dystrophy type 1/DM1. This designation is based on data from the ongoing DELIVER clinical trial. DYNE-251 has shown sustained functional improvements over 18 months, measured by key metrics like time to rise and stride velocity.

The therapy also demonstrated the production of near-full-length dystrophin protein. The FDA grants this designation to expedite the development and review of drugs for serious conditions that show preliminary evidence of a substantial improvement over existing treatments. The benefits for DYNE-251 include enhanced FDA support, early and frequent communication with reviewers, and eligibility for rolling and Priority Review, which could reduce the Biologics License Application/BLA review period from 12 to 8 months.

Dyne Therapeutics Inc. (NASDAQ:DYN) is a clinical-stage neuromuscular disease company that focuses on discovering and developing therapeutics for neuromuscular diseases in the US.

While we acknowledge the potential of DYN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.